Combination of simvastatin with berberine improves the lipid-lowering efficacy

Metabolism: Clinical and Experimental

Volumn 57, Issue 8, 2008, Pages 1029-1037

  Kong, Wei Jia ^a   Wei, Jin ^b   Zuo, Zeng Yan ^a   Wang, Yue Ming ^a   Song, Dan Qing ^a   You, Xue Fu ^a   Zhao, Li Xun ^a   Pan, Huai Ning ^b   Jiang, Jian Dong ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID STORAGE; LIVER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BERBERINE; CHOLESTEROL, LDL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; RATS; RATS, WISTAR; RECEPTORS, LDL; RNA, MESSENGER; SIMVASTATIN; TRIGLYCERIDES; UP-REGULATION;

EID: 47149089693     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.01.037     Document Type: Article

References (33)

1. Balbisi E.A. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. Med Sci Monit 12 (2006) RA34-RA39
2. Stamler J., Daviglus M.L., Garside D.B., et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 284 (2000) 311-318
3. Anderson K.M., Castelli W.P., and Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 257 (1987) 2176-2180
4. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
5. Klotz U. Pharmacological comparison of the statins. Arzneimittelforschung 53 (2003) 605-611
6. Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84 (1999) 413-428
7. Moghadasian M.H. A safety look at currently available statins. Expert Opin Drug Saf 1 (2002) 269-274
8. Stein E.A. New statins and new doses of older statins. Curr Atheroscler Rep 3 (2001) 14-18
9. Mckenney J. Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. Am J Cardiol 90 (2002) 8K-20K
10. Farmer J.A., and Gotto Jr. A.M. Antihyperlipidaemic agents. Drug interactions of clinical significance. Drug Saf 11 (1994) 301-309
11. Jones P., Kafonek S., Laurora I., et al. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
12. Brown A.S., Bakker-Arkema R.G., Yellen L., et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 32 (1998) 665-672
13. Brown A.S. Use of combination therapy for dyslipidemia: a lipid clinic approach. Am J Cardiol 90 (2002) 44K-49K
14. Hunninghake D., Insull Jr. W., Toth P., et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158 (2001) 407-416
15. Davidson M.H. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 90 (2002) 50K-60K
16. Knapp H.H., Schrott H., Ma P., et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 110 (2001) 352-360
17. Gupta E.K., and Ito M.K. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis 4 (2002) 124-137
18. Wolfe M.L., Vartanian S.F., Ross J.L., et al. Safety and effectiveness of extended-release niacin when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 87 (2001) 476-479
19. Pearson T., Denke M., McBride P., et al. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients, subanalysis of data from a randomized, double-blind, placebo-controlled trial. Am J Geriatr Pharmacother 3 (2005) 218-228
20. Robinson J.G., and Davidson M.H. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther 4 (2006) 461-476
21. Kong W., Wei J., Abidi P., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10 (2004) 1344-1351
22. Kong W., Abidi P., Kraemer F.B., et al. In vivo activities of cytokine oncostatin M in the regulation of plasma lipid levels. J Lipid Res 46 (2005) 1163-1171
23. Mani U.V., Sharma M., Waghray K., et al. Effect of colocasia leaves (Colocasia antiquorum) on serum and tissue lipids in cholesterol-fed rats. Plant Foods Hum Nutr 39 (1989) 245-255
24. Van Itallie T.B., Hashim S.A., Crampton R.S., et al. The treatment of pruritus and hypercholesterolemia of primary biliary cirrhosis with cholestyramine. N Engl J Med 265 (1961) 469-474
25. Bruckert E., Giral P., and Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 107 (2003) 3124-3128
26. Sprecher D.L., Abrams J., Allen J.W., et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 120 (1994) 537-543
27. Kong W., Liu J., and Jiang J.D. Human low-density lipoprotein receptor gene and its regulation. J Mol Med 84 (2006) 29-36
28. Abidi P., Zhou Y., Jiang J.D., et al. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 25 (2005) 2170-2176
29. Oms P., Assie N., Bruniquel F., et al. Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-coenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate. Pharmacol Toxicol 77 (1995) 391-396
30. Morand O.H., Aebi J.D., Dehmlow H., et al. Ro 48-8071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys and minipigs: comparison to simvastatin. J Lipid Research 38 (1997) 373-390
31. Yokozawa T., Ishida A., Cho E.J., et al. The effects of Coptidis Rhizoma extract on a hypercholesterolemic animal model. Phytomedicine 10 (2003) 17-22
32. Schectman G., and Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 125 (1996) 990-1000
33. Brusq J.M., Ancellin N., Grondin P., et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47 (2006) 1281-1288